{"schemaVersion":"2.1","datasetVersion":"2026-07-24.2","generatedAt":"2026-07-24","reviewStatus":"Editorial source review completed; not independently medically reviewed","editorialBoundary":"Educational evidence summaries only. No dosing, sourcing, reconstitution, injection, cycling, stacking, or self-treatment instructions.","citation":"Cite The Peptide Field, the record canonicalPath, dataset version 2026-07-24.2, and every underlying source used for the claim.","reuse":"No additional reuse license is granted by this endpoint. Preserve verdict, scope, evidence basis, review date, and source links together; do not present a record as medical advice or medical review.","changeLogPath":"/corrections#correction-ledger","contactPath":"/corrections","dataset":"claims","count":60,"records":[{"claim":"“Semaglutide is FDA-approved.”","verdict":"Supported with scope","explanation":"Some drug products containing semaglutide are FDA-approved for specific uses. The product, formulation, and indication matter.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"Specific FDA-approved semaglutide products, formulations, populations, and indications in their current labels.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf"],"id":"claim-semaglutide-approval","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-semaglutide-approval","peptideName":"Semaglutide","peptideSlug":"semaglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Compounded semaglutide is the same as an approved product.”","verdict":"Misleading","explanation":"FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Compounded or otherwise unapproved semaglutide products compared with FDA-approved products.","sourceUrls":["https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"],"id":"claim-semaglutide-compounded-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-semaglutide-compounded-equivalence","peptideName":"Semaglutide","peptideSlug":"semaglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“A result in one population proves the same benefit for everyone.”","verdict":"Not established","explanation":"Trial population, endpoint, formulation, dose, duration, and indication define what a study can support.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"The populations, formulations, endpoints, and durations described in the cited approved-product record.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf"],"id":"claim-semaglutide-population-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-semaglutide-population-transfer","peptideName":"Semaglutide","peptideSlug":"semaglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf","sourceKind":"Drug label","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Insulin is an established treatment for diabetes.”","verdict":"Supported with scope","explanation":"Multiple insulin products are FDA-approved, and long-term human evidence supports insulin strategies in defined diabetes populations. The exact product and care context still matter.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"FDA-approved insulin products and monitored treatment strategies in defined diabetes populations.","sourceUrls":["https://www.fda.gov/consumers/free-publications-women/insulin","https://pubmed.ncbi.nlm.nih.gov/8366922/"],"id":"claim-insulin-established-treatment","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-insulin-established-treatment","peptideName":"Insulin","peptideSlug":"insulin","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/consumers/free-publications-women/insulin","sourceKind":"Regulatory","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/8366922/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“All insulin products work the same way and can be swapped freely.”","verdict":"Misleading","explanation":"Insulin products differ in timing, concentration, delivery system, and approved labeling. A switch can require clinical oversight and product-specific instructions.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Product-specific insulin formulations, concentrations, delivery systems, and labels.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020563s214%2C205747s038lbl.pdf","https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes"],"id":"claim-insulin-product-interchangeability","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-insulin-product-interchangeability","peptideName":"Insulin","peptideSlug":"insulin","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020563s214%2C205747s038lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."},{"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“More intensive insulin treatment is always better.”","verdict":"Misleading","explanation":"The DCCT found important complication reductions alongside substantially more severe hypoglycemia. Treatment intensity must be individualized and monitored.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"The monitored intensive-treatment strategy and type 1 diabetes population studied in the DCCT.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/8366922/","https://pubmed.ncbi.nlm.nih.gov/9000705/"],"id":"claim-insulin-treatment-intensity","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-insulin-treatment-intensity","peptideName":"Insulin","peptideSlug":"insulin","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/8366922/","sourceKind":"Randomized trial","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/9000705/","sourceKind":"Randomized trial","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Tirzepatide has established human outcome evidence for defined metabolic indications.”","verdict":"Supported with scope","explanation":"Approved product labels and large randomized trials support specific glycemic and weight outcomes in defined populations.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Mounjaro and Zepbound in the labeled and trial populations, endpoints, comparators, and durations.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf","https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf","https://pubmed.ncbi.nlm.nih.gov/35658024/","https://pubmed.ncbi.nlm.nih.gov/34170647/"],"id":"claim-tirzepatide-defined-outcomes","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tirzepatide-defined-outcomes","peptideName":"Tirzepatide","peptideSlug":"tirzepatide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/34170647/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”","verdict":"Not established","explanation":"Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/35658024/","https://pubmed.ncbi.nlm.nih.gov/34170647/"],"id":"claim-tirzepatide-universal-response","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tirzepatide-universal-response","peptideName":"Tirzepatide","peptideSlug":"tirzepatide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/34170647/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Compounded tirzepatide is equivalent to an approved product.”","verdict":"Misleading","explanation":"FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Compounded or otherwise unapproved tirzepatide compared with approved Mounjaro or Zepbound.","sourceUrls":["https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"],"id":"claim-tirzepatide-compounded-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tirzepatide-compounded-equivalence","peptideName":"Tirzepatide","peptideSlug":"tirzepatide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“BPC-157 improves tendon healing in preclinical models.”","verdict":"Supported with scope","explanation":"Cell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.","category":"Performance and recovery","evidenceBasis":"Preclinical evidence","scope":"Cell and animal tendon models only; not clinical healing outcomes in people.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/21030672/"],"id":"claim-bpc-157-preclinical-tendon","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bpc-157-preclinical-tendon","peptideName":"BPC-157","peptideSlug":"bpc-157","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/21030672/","sourceKind":"Preclinical","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's preclinical evidence basis and stated scope."}]},{"claim":"“BPC-157 heals tendons and muscles in people.”","verdict":"Not established","explanation":"Early human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.","category":"Performance and recovery","evidenceBasis":"No reliable human outcome evidence","scope":"Human tendon and muscle-healing claims; existing pilots and a trial registration do not establish benefit.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/42198317/","https://pubmed.ncbi.nlm.nih.gov/40131143/","https://clinicaltrials.gov/study/NCT07437547"],"id":"claim-bpc-157-human-healing","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bpc-157-human-healing","peptideName":"BPC-157","peptideSlug":"bpc-157","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/42198317/","sourceKind":"Science review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/40131143/","sourceKind":"Human pilot","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."},{"url":"https://clinicaltrials.gov/study/NCT07437547","sourceKind":"Trial registry","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Athletes can use it because it is not a steroid.”","verdict":"Misleading","explanation":"WADA lists BPC-157 under S0 non-approved substances, prohibited at all times for covered athletes.","category":"Performance and recovery","evidenceBasis":"Regulatory or product record","scope":"Athletes subject to the current WADA Code and their applicable governing-body rules.","sourceUrls":["https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list"],"id":"claim-bpc-157-athlete-status","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bpc-157-athlete-status","peptideName":"BPC-157","peptideSlug":"bpc-157","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list","sourceKind":"Anti-doping","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“CJC-1295 can raise GH and IGF-1 in healthy adults.”","verdict":"Supported with scope","explanation":"Randomized human studies reported sustained hormone increases. This supports a biomarker effect, not a patient benefit.","category":"Mechanism and biomarkers","evidenceBasis":"Human pharmacology","scope":"Short-term GH and IGF-1 pharmacodynamic responses in the healthy adults studied.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/16352683/","https://pubmed.ncbi.nlm.nih.gov/17018654/"],"id":"claim-cjc-1295-human-pharmacology","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-cjc-1295-human-pharmacology","peptideName":"CJC-1295","peptideSlug":"cjc-1295","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's human pharmacology basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/17018654/","sourceKind":"Human pharmacology","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's human pharmacology basis and stated scope."}]},{"claim":"“CJC-1295 builds muscle and burns fat in people.”","verdict":"Not established","explanation":"The identified trials were not designed to establish durable improvements in body composition or function.","category":"Performance and recovery","evidenceBasis":"No reliable human outcome evidence","scope":"Clinical body-composition and functional outcomes, which the cited pharmacology studies did not test.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/16352683/","https://pubmed.ncbi.nlm.nih.gov/17018654/"],"id":"claim-cjc-1295-body-outcomes","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-cjc-1295-body-outcomes","peptideName":"CJC-1295","peptideSlug":"cjc-1295","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/17018654/","sourceKind":"Human pharmacology","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“All products called CJC-1295 are interchangeable.”","verdict":"Misleading","explanation":"The literature and commercial market may refer to different molecular forms, salts, modifications, and combinations.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Products marketed as CJC-1295 with different forms, salts, modifications, combinations, or quality controls.","sourceUrls":["https://www.fda.gov/media/183819/download","https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"],"id":"claim-cjc-1295-product-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-cjc-1295-product-equivalence","peptideName":"CJC-1295","peptideSlug":"cjc-1295","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/183819/download","sourceKind":"FDA review","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."},{"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Ipamorelin stimulates GH release in people.”","verdict":"Supported with scope","explanation":"A human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.","category":"Mechanism and biomarkers","evidenceBasis":"Human pharmacology","scope":"Short-term GH pharmacodynamics in the healthy volunteers and route studied.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/10496658/"],"id":"claim-ipamorelin-human-pharmacology","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ipamorelin-human-pharmacology","peptideName":"Ipamorelin","peptideSlug":"ipamorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/10496658/","sourceKind":"Human pharmacology","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's human pharmacology basis and stated scope."}]},{"claim":"“A GH response proves better recovery or body composition.”","verdict":"Not established","explanation":"A biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.","category":"Performance and recovery","evidenceBasis":"No reliable human outcome evidence","scope":"Recovery and body-composition outcomes not established by GH pharmacology or the postoperative-ileus trial.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/10496658/","https://pubmed.ncbi.nlm.nih.gov/25331030/"],"id":"claim-ipamorelin-biomarker-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ipamorelin-biomarker-transfer","peptideName":"Ipamorelin","peptideSlug":"ipamorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/10496658/","sourceKind":"Human pharmacology","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."},{"url":"https://pubmed.ncbi.nlm.nih.gov/25331030/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Ipamorelin worked in its phase 2 surgical trial.”","verdict":"Misleading","explanation":"The randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"The postoperative-ileus population, intervention, and efficacy endpoints in the phase 2 trial.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/25331030/"],"id":"claim-ipamorelin-phase-2-outcome","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ipamorelin-phase-2-outcome","peptideName":"Ipamorelin","peptideSlug":"ipamorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/25331030/","sourceKind":"Randomized trial","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Liraglutide has established human outcome evidence.”","verdict":"Supported with scope","explanation":"Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Approved liraglutide products used in the populations and indications studied.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/27295427/","https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf"],"id":"claim-liraglutide-defined-outcomes","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-liraglutide-defined-outcomes","peptideName":"Liraglutide","peptideSlug":"liraglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Every product sold as liraglutide is clinically equivalent.”","verdict":"Misleading","explanation":"Approved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Product identity, formulation, quality, and labeling all matter.","sourceUrls":["https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases"],"id":"claim-liraglutide-product-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-liraglutide-product-equivalence","peptideName":"Liraglutide","peptideSlug":"liraglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Cardiovascular trial results prove a universal longevity benefit.”","verdict":"Not established","explanation":"LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.","category":"Longevity","evidenceBasis":"Randomized human outcomes","scope":"Adults with type 2 diabetes and high cardiovascular risk in LEADER.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/27295427/"],"id":"claim-liraglutide-longevity-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-liraglutide-longevity-transfer","peptideName":"Liraglutide","peptideSlug":"liraglutide","family":"Metabolic peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Retatrutide caused weight loss in a randomized human trial.”","verdict":"Supported with scope","explanation":"The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Adults meeting the phase 2 obesity-trial criteria over 48 weeks.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/37366315/"],"id":"claim-retatrutide-phase-2-weight","version":1,"reviewedAtISO":"2026-07-24","canonicalPath":"/claims/claim-retatrutide-phase-2-weight","peptideName":"Retatrutide","peptideSlug":"retatrutide","family":"Metabolic peptide medicines","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-24","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Retatrutide is FDA-approved.”","verdict":"Misleading","explanation":"It remains investigational. Positive trial results and sponsor announcements are not FDA marketing approval.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"United States regulatory status as reviewed July 24, 2026.","sourceUrls":["https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"],"id":"claim-retatrutide-approval-status","version":1,"reviewedAtISO":"2026-07-24","canonicalPath":"/claims/claim-retatrutide-approval-status","peptideName":"Retatrutide","peptideSlug":"retatrutide","family":"Metabolic peptide medicines","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-24","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Research retatrutide sold online is the same as clinical-trial material.”","verdict":"Not established","explanation":"A matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence.","category":"Product equivalence","evidenceBasis":"No reliable human outcome evidence","scope":"Products outside an authorized clinical-development supply chain.","sourceUrls":["https://clinicaltrials.gov/study/NCT05929066","https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"],"id":"claim-retatrutide-product-equivalence","version":1,"reviewedAtISO":"2026-07-24","canonicalPath":"/claims/claim-retatrutide-product-equivalence","peptideName":"Retatrutide","peptideSlug":"retatrutide","family":"Metabolic peptide medicines","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-24","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://clinicaltrials.gov/study/NCT05929066","sourceKind":"Trial registry","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."},{"url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","sourceKind":"Regulatory","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”","verdict":"Supported with scope","explanation":"Phase 3 trials and the product label support this outcome in the labeled population.","category":"Body composition","evidenceBasis":"Randomized human outcomes","scope":"Adults with HIV and excess abdominal fat meeting the trial and label criteria.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/20101189/","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf"],"id":"claim-tesamorelin-labeled-outcome","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tesamorelin-labeled-outcome","peptideName":"Tesamorelin","peptideSlug":"tesamorelin","family":"Growth signaling","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Tesamorelin is an approved general weight-loss drug.”","verdict":"Misleading","explanation":"The label specifically says it is not indicated for weight-loss management.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"The current Egrifta SV and Egrifta WR labels.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf"],"id":"claim-tesamorelin-general-weight-loss","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tesamorelin-general-weight-loss","peptideName":"Tesamorelin","peptideSlug":"tesamorelin","family":"Growth signaling","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Tesamorelin is permitted for competitive athletes.”","verdict":"Misleading","explanation":"The 2026 WADA Prohibited List names tesamorelin.","category":"Performance and recovery","evidenceBasis":"Regulatory or product record","scope":"Sport governed by the World Anti-Doping Code.","sourceUrls":["https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list"],"id":"claim-tesamorelin-athlete-status","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tesamorelin-athlete-status","peptideName":"Tesamorelin","peptideSlug":"tesamorelin","family":"Growth signaling","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list","sourceKind":"Anti-doping","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Sermorelin was once FDA-approved.”","verdict":"Supported with scope","explanation":"Geref approvals are documented. FDA later determined that the discontinued products were not withdrawn for reasons of safety or effectiveness.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"Historical Geref products, not current compounded sermorelin.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf","https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf"],"id":"claim-sermorelin-historical-approval","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-sermorelin-historical-approval","peptideName":"Sermorelin","peptideSlug":"sermorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019863_S001_GEREF.pdf","sourceKind":"FDA review","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."},{"url":"https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf","sourceKind":"Regulatory","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Sermorelin raises growth hormone, so it is proven to slow aging.”","verdict":"Misleading","explanation":"A hormone response is not a patient-centered aging or longevity outcome.","category":"Longevity","evidenceBasis":"Human pharmacology","scope":"Hormone-response evidence cannot establish longer life or slower biological aging.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/18031173/"],"id":"claim-sermorelin-longevity-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-sermorelin-longevity-transfer","peptideName":"Sermorelin","peptideSlug":"sermorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/18031173/","sourceKind":"Science review","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's human pharmacology basis and stated scope."}]},{"claim":"“Compounded sermorelin is an FDA-approved Geref generic.”","verdict":"Misleading","explanation":"The historical product record does not make current compounded products approved or equivalent.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Current products marketed after Geref withdrawal.","sourceUrls":["https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf"],"id":"claim-sermorelin-product-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-sermorelin-product-equivalence","peptideName":"Sermorelin","peptideSlug":"sermorelin","family":"Growth signaling","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“TB-500 is the same thing as thymosin beta-4.”","verdict":"Misleading","explanation":"FDA describes TB-500 as a seven-amino-acid fragment of the much larger thymosin beta-4 molecule.","category":"Mechanism and biomarkers","evidenceBasis":"Regulatory or product record","scope":"Chemical identity, not a claim about all possible biological activity.","sourceUrls":["https://www.fda.gov/media/193349/download"],"id":"claim-tb-500-identity","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tb-500-identity","peptideName":"TB-500","peptideSlug":"tb-500","family":"Recovery and repair claims","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193349/download","sourceKind":"FDA review","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“TB-500 accelerates tendon and muscle healing in people.”","verdict":"Not established","explanation":"The FDA evidence review did not identify adequate human outcome evidence for wound-healing use.","category":"Performance and recovery","evidenceBasis":"No reliable human outcome evidence","scope":"Clinical tendon, muscle, and wound-healing outcomes in people.","sourceUrls":["https://www.fda.gov/media/193349/download"],"id":"claim-tb-500-human-healing","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tb-500-human-healing","peptideName":"TB-500","peptideSlug":"tb-500","family":"Recovery and repair claims","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193349/download","sourceKind":"FDA review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“TB-500 is allowed in tested sport.”","verdict":"Misleading","explanation":"TB-500 is named on the current WADA Prohibited List.","category":"Performance and recovery","evidenceBasis":"Regulatory or product record","scope":"Sport governed by the World Anti-Doping Code.","sourceUrls":["https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list"],"id":"claim-tb-500-athlete-status","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-tb-500-athlete-status","peptideName":"TB-500","peptideSlug":"tb-500","family":"Recovery and repair claims","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list","sourceKind":"Anti-doping","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“GHK-Cu has been studied in people.”","verdict":"Supported with scope","explanation":"Yes, but the cited topical trial had 13 completers, found no significant objective improvement in erythema, wrinkles, or skin quality, and reported higher patient satisfaction. It does not establish broader outcomes or other routes.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"A specific topical copper-tripeptide formulation after CO2 laser resurfacing.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/16847171/"],"id":"claim-ghk-cu-human-study","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ghk-cu-human-study","peptideName":"GHK-Cu","peptideSlug":"ghk-cu","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/16847171/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Topical GHK-Cu evidence proves injectable GHK-Cu works systemically.”","verdict":"Misleading","explanation":"Route, formulation, exposure, product quality, and endpoint differ. Evidence cannot be transferred by ingredient name alone.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Topical study formulations versus compounded injectable products.","sourceUrls":["https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"],"id":"claim-ghk-cu-route-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ghk-cu-route-transfer","peptideName":"GHK-Cu","peptideSlug":"ghk-cu","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Injectable GHK-Cu is proven safe.”","verdict":"Not established","explanation":"FDA identifies limited human data and potential immunogenicity related to aggregation and peptide impurities.","category":"Safety","evidenceBasis":"Regulatory or product record","scope":"Compounded injectable GHK-Cu.","sourceUrls":["https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"],"id":"claim-ghk-cu-injectable-safety","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-ghk-cu-injectable-safety","peptideName":"GHK-Cu","peptideSlug":"ghk-cu","family":"Recovery and repair claims","tier":"Emerging","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","sourceKind":"Regulatory","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“MOTS-c has promising metabolic effects in animal research.”","verdict":"Supported with scope","explanation":"Preclinical metabolic findings are a real research signal, but they remain preclinical.","category":"Mechanism and biomarkers","evidenceBasis":"Preclinical evidence","scope":"Laboratory and animal research, not patient outcomes.","sourceUrls":["https://www.fda.gov/media/193347/download"],"id":"claim-mots-c-preclinical-metabolic","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-mots-c-preclinical-metabolic","peptideName":"MOTS-c","peptideSlug":"mots-c","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193347/download","sourceKind":"FDA review","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's preclinical evidence basis and stated scope."}]},{"claim":"“MOTS-c produces weight loss in people.”","verdict":"Not established","explanation":"FDA found no published human drug-product administration studies in its 2026 review.","category":"Body composition","evidenceBasis":"No reliable human outcome evidence","scope":"Clinical weight outcomes from administered MOTS-c drug products.","sourceUrls":["https://www.fda.gov/media/193347/download"],"id":"claim-mots-c-human-weight","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-mots-c-human-weight","peptideName":"MOTS-c","peptideSlug":"mots-c","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193347/download","sourceKind":"FDA review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“A UNII number means MOTS-c is FDA-approved.”","verdict":"Misleading","explanation":"FDA's substance registry explicitly states that UNII availability does not imply regulatory review or approval.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"Substance identification versus drug-product approval.","sourceUrls":["https://precision.fda.gov/uniisearch/srs/unii/A5CV6JFB78"],"id":"claim-mots-c-unii-approval","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-mots-c-unii-approval","peptideName":"MOTS-c","peptideSlug":"mots-c","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://precision.fda.gov/uniisearch/srs/unii/A5CV6JFB78","sourceKind":"Reference","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“AOD-9604 has been given to people in clinical studies.”","verdict":"Supported with scope","explanation":"FDA's review describes several human studies, primarily using oral or intravenous routes.","category":"Clinical outcomes","evidenceBasis":"Regulatory or product record","scope":"Historical study products and routes described in FDA's review.","sourceUrls":["https://www.fda.gov/media/183584/download"],"id":"claim-aod-9604-human-exposure","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-aod-9604-human-exposure","peptideName":"AOD-9604","peptideSlug":"aod-9604","family":"Metabolic peptide medicines","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/183584/download","sourceKind":"FDA review","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Human exposure proves AOD-9604 is an effective fat-loss drug.”","verdict":"Misleading","explanation":"Exposure and tolerability data do not establish a clinically meaningful weight-loss outcome.","category":"Body composition","evidenceBasis":"No reliable human outcome evidence","scope":"Weight-loss efficacy, not merely participation in a study.","sourceUrls":["https://www.fda.gov/media/183584/download"],"id":"claim-aod-9604-fat-loss","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-aod-9604-fat-loss","peptideName":"AOD-9604","peptideSlug":"aod-9604","family":"Metabolic peptide medicines","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/183584/download","sourceKind":"FDA review","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Injectable AOD-9604 has a well-characterized safety profile.”","verdict":"Not established","explanation":"FDA identifies limited safety data, immunogenicity concerns, and missing information for proposed injectable use.","category":"Safety","evidenceBasis":"Regulatory or product record","scope":"Compounded injectable AOD-9604.","sourceUrls":["https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"],"id":"claim-aod-9604-injectable-safety","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-aod-9604-injectable-safety","peptideName":"AOD-9604","peptideSlug":"aod-9604","family":"Metabolic peptide medicines","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","sourceKind":"Regulatory","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Epitalon changes telomere biology in human cell lines.”","verdict":"Supported with scope","explanation":"A 2025 laboratory study reported telomere-length effects in cultured human cell lines.","category":"Mechanism and biomarkers","evidenceBasis":"Preclinical evidence","scope":"Cultured cell lines, not health outcomes in treated people.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/40908429/"],"id":"claim-epitalon-cell-telomeres","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-epitalon-cell-telomeres","peptideName":"Epitalon","peptideSlug":"epitalon","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/40908429/","sourceKind":"Preclinical","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's preclinical evidence basis and stated scope."}]},{"claim":"“Epitalon is proven to treat insomnia.”","verdict":"Not established","explanation":"FDA did not identify clinical insomnia studies of the nominated epitalon substances by the proposed route.","category":"Clinical outcomes","evidenceBasis":"No reliable human outcome evidence","scope":"Adults with insomnia assessed using clinical sleep outcomes.","sourceUrls":["https://www.fda.gov/media/193345/download"],"id":"claim-epitalon-insomnia","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-epitalon-insomnia","peptideName":"Epitalon","peptideSlug":"epitalon","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193345/download","sourceKind":"FDA review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Epitalon has been proven to extend human lifespan.”","verdict":"Not established","explanation":"The evidence does not provide reliable product-specific randomized lifespan outcomes for epitalon.","category":"Longevity","evidenceBasis":"No reliable human outcome evidence","scope":"Human lifespan and healthspan outcomes attributable to epitalon.","sourceUrls":["https://www.fda.gov/media/193345/download"],"id":"claim-epitalon-human-lifespan","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-epitalon-human-lifespan","peptideName":"Epitalon","peptideSlug":"epitalon","family":"Longevity and cellular signaling","tier":"Insufficient","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.fda.gov/media/193345/download","sourceKind":"FDA review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's no reliable human outcome evidence basis and stated scope."}]},{"claim":"“Bremelanotide is FDA-approved for a specific form of HSDD.”","verdict":"Supported with scope","explanation":"Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"The population and limitations in the current Vyleesi label.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf"],"id":"claim-bremelanotide-labeled-indication","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bremelanotide-labeled-indication","peptideName":"Bremelanotide","peptideSlug":"bremelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“PT-141 is an approved sexual-performance enhancer for anyone.”","verdict":"Misleading","explanation":"The label explicitly says the product is not for enhancing sexual performance and is not indicated for men or postmenopausal women.","category":"Clinical outcomes","evidenceBasis":"Regulatory or product record","scope":"Vyleesi's labeled indication and limitations.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf"],"id":"claim-bremelanotide-broad-performance","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bremelanotide-broad-performance","peptideName":"Bremelanotide","peptideSlug":"bremelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Compounded PT-141 has the same evidence as Vyleesi.”","verdict":"Not established","explanation":"The trial and approval record are product-specific and do not establish equivalence for compounded material.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Compounded or research-labeled bremelanotide products.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf"],"id":"claim-bremelanotide-product-equivalence","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-bremelanotide-product-equivalence","peptideName":"Bremelanotide","peptideSlug":"bremelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf","sourceKind":"FDA review","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Afamelanotide increases pain-free light exposure in adults with EPP.”","verdict":"Supported with scope","explanation":"The label and randomized trials support this defined rare-disease outcome.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Adults with a history of phototoxic reactions from erythropoietic protoporphyria.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/26132941/","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf"],"id":"claim-afamelanotide-epp-outcome","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-afamelanotide-epp-outcome","peptideName":"Afamelanotide","peptideSlug":"afamelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/26132941/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Scenesse is an approved cosmetic tanning implant.”","verdict":"Misleading","explanation":"Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.","category":"Approval and status","evidenceBasis":"Regulatory or product record","scope":"The current FDA-approved indication.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf"],"id":"claim-afamelanotide-cosmetic-tanning","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-afamelanotide-cosmetic-tanning","peptideName":"Afamelanotide","peptideSlug":"afamelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Afamelanotide evidence proves other tanning peptides are safe and effective.”","verdict":"Misleading","explanation":"Different molecules and products require their own identity, quality, safety, and outcome evidence.","category":"Product equivalence","evidenceBasis":"Regulatory or product record","scope":"Other melanocortin analogues and unapproved products.","sourceUrls":["https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208"],"id":"claim-afamelanotide-evidence-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-afamelanotide-evidence-transfer","peptideName":"Afamelanotide","peptideSlug":"afamelanotide","family":"Melanocortin medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208","sourceKind":"Regulatory","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Teriparatide reduces fracture risk in defined osteoporosis populations.”","verdict":"Supported with scope","explanation":"The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Labeled osteoporosis populations at high fracture risk.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/11248153/","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf"],"id":"claim-teriparatide-fracture-risk","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teriparatide-fracture-risk","peptideName":"Teriparatide","peptideSlug":"teriparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/11248153/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Teriparatide is proven to heal every fracture faster.”","verdict":"Not established","explanation":"Fracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.","category":"Performance and recovery","evidenceBasis":"Randomized human outcomes","scope":"Acute fracture-healing outcomes across all fracture types.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/26932738/"],"id":"claim-teriparatide-fracture-healing","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teriparatide-fracture-healing","peptideName":"Teriparatide","peptideSlug":"teriparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/26932738/","sourceKind":"Randomized trial","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Because teriparatide is a peptide, it has no serious risks.”","verdict":"Misleading","explanation":"The current label includes clinically important warnings, precautions, and population restrictions.","category":"Safety","evidenceBasis":"Regulatory or product record","scope":"Approved teriparatide product use.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf"],"id":"claim-teriparatide-safety","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teriparatide-safety","peptideName":"Teriparatide","peptideSlug":"teriparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Abaloparatide reduced fractures in a randomized phase 3 trial.”","verdict":"Supported with scope","explanation":"ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Postmenopausal women with osteoporosis at fracture risk over 18 months.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/27533157/"],"id":"claim-abaloparatide-phase-3-fractures","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-abaloparatide-phase-3-fractures","peptideName":"Abaloparatide","peptideSlug":"abaloparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/27533157/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Abaloparatide is proven to improve bone outcomes in every population.”","verdict":"Not established","explanation":"Approved indications and trial populations define the evidence boundary.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Populations outside the current label and pivotal trial.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf"],"id":"claim-abaloparatide-population-transfer","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-abaloparatide-population-transfer","peptideName":"Abaloparatide","peptideSlug":"abaloparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf","sourceKind":"Drug label","relationship":"Defines the evidence limit","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“An anabolic bone effect means abaloparatide is a safe performance enhancer.”","verdict":"Misleading","explanation":"A prescription osteoporosis benefit-risk assessment does not establish safe enhancement in healthy people.","category":"Performance and recovery","evidenceBasis":"Regulatory or product record","scope":"Healthy or athletic performance use.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf"],"id":"claim-abaloparatide-performance-safety","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-abaloparatide-performance-safety","peptideName":"Abaloparatide","peptideSlug":"abaloparatide","family":"Bone and tissue peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743Orig1s017lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”","verdict":"Supported with scope","explanation":"Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.","category":"Clinical outcomes","evidenceBasis":"Randomized human outcomes","scope":"Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.","sourceUrls":["https://pubmed.ncbi.nlm.nih.gov/22982184/","https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"],"id":"claim-teduglutide-parenteral-support","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teduglutide-parenteral-support","peptideName":"Teduglutide","peptideSlug":"teduglutide","family":"Gut and intestinal peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/22982184/","sourceKind":"Randomized trial","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf","sourceKind":"Drug label","relationship":"Supports the scoped claim","rationale":"Reviewed against this claim's randomized human outcomes basis and stated scope."}]},{"claim":"“Teduglutide is a general gut-healing peptide.”","verdict":"Misleading","explanation":"The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.","category":"Clinical outcomes","evidenceBasis":"Regulatory or product record","scope":"The current Gattex indication.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"],"id":"claim-teduglutide-general-gut-healing","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teduglutide-general-gut-healing","peptideName":"Teduglutide","peptideSlug":"teduglutide","family":"Gut and intestinal peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]},{"claim":"“Because teduglutide promotes intestinal growth, it is low risk.”","verdict":"Misleading","explanation":"The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.","category":"Safety","evidenceBasis":"Regulatory or product record","scope":"Approved Gattex use with required screening and monitoring.","sourceUrls":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"],"id":"claim-teduglutide-safety","version":1,"reviewedAtISO":"2026-07-23","canonicalPath":"/claims/claim-teduglutide-safety","peptideName":"Teduglutide","peptideSlug":"teduglutide","family":"Gut and intestinal peptide medicines","tier":"Established","sourceReview":{"status":"Internal editorial review recorded","reviewedBy":"Anthony Treviso","reviewerRole":"Founder and responsible editor","reviewedAtISO":"2026-07-23","independentClinicalReview":false,"boundary":"No physician or pharmacist is currently represented as an independent medical reviewer. Clinical review will be named with credentials, scope, date, and conflicts only after it occurs."},"sourceRoles":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf","sourceKind":"Drug label","relationship":"Supports the corrective verdict","rationale":"Reviewed against this claim's regulatory or product record basis and stated scope."}]}]}